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Abstract
Our purpose was to evaluate associations of single nucleotide polymorphisms (SNPs) at the low 
density lipoprotein (LDL) receptor (LDLR C44857T, minor allele frequency (MAF) 0.26, and 
A44964G, MAF 0.25, both in the untranslated region) and HMG-CoA reductase (HMGCR 
i18T>G, MAF 0.019) gene loci with baseline lipid values, statin induced LDL- cholesterol (C) 
lowering response, and incident coronary heart disease (CHD) and cardiovascular disease on trial 
(CVD). Our population consisted of 5804 elderly men and women with vascular disease or one or 
more vascular disease risk factors, who were randomly allocated to pravastatin or placebo. Other 
risk factors and apolipoprotein (apo) E phenotype were controlled for in the analysis. Despite a 
prior report, no relationships with the HMGCR SNP were noted. For the LDLR SNPs C44857T 
and A44964G we noted significant associations of the rare alleles with baseline LDL-C and 
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triglyceride levels, a modest association of the C44857T with LDL-C lowering to pravastatin in 
men, and significant associations with incident CHD and CVD of both SNPs, especially in men on 
pravastatin. Our data indicate that genetic variation at the LDLR locus can affect baseline lipids, 
response to pravastatin, and CVD risk in subjects placed on statin treatment.
Keywords
Genetics; Statins; Low density lipoproteins (LDL); Coronary Heart Disease (CHD); HMGCR 
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Elevated levels of plasma low density lipoprotein (LDL) cholesterol (C) are a major 
independent risk factor for coronary heart disease (CHD) and cardiovascular disease (CVD, 
CHD plus stroke). The LDL receptor (R) plays a critical role in the catabolism of LDL1. 
Moreover 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase (HMGCR) is 
the rate limiting enzyme in cholesterol synthesis, and statins are competitive inhibitors of 
this process. Statin therapy has been shown to lower LDL levels because of enhanced 
fractional clearance related to upregulation of LDL receptor activity. Mutations at the LDLR 
gene locus are the cause of familial hypercholesterolemia2,3, and these subjects have 
markedly elevated plasma LDL-C levels and premature death and disability from CHD4. 
Genetic variation at the LDLR gene locus in the general population can also affect LDL-C. 
Muallem et al. reported that single nucleotide polymorphisms (SNPs) at the 3’UTR 
significantly alter plasma LDL-C levels in Caucasian, but not in African American 
subjects5. Chasman et al. reported that the presence of two highly linked SNPs in HMGCR 
was related to pravastatin induced LDL-C lowering response6.
Our aim was to determine if SNPs at the 3’UTR LDLR region and in intron 18 at HMGCR 
could be related to baseline lipids, baseline vascular disease, lipid lowering response to 
pravastatin, and CHD and CVD risk in the PROSPER (Prospective Study of Pravastatin in 
the Elderly at Risk) Study. In this study 5804 male and female subjects, mean age 75.3 
years, were selected for having a history of vascular disease or CHD risk factors (smoking, 
hypertension, or diabetes), and were randomized to either pravastatin 40 mg/day or placebo 
and were followed for a mean of 3.2 years.10 The use of pravastatin in PROSPER was 
associated with significant CHD risk reduction as compared to the placebo group.
Materials and Methods
Study Subjects
The protocol of PROSPER has previously been published7, as have the PROSPER results.8 
In this study 2804 men and 3000 women, aged 70 to 82, with pre-existing vascular disease 
or at least one of three major vascular risk factors (diabetes, smoking, or hypertension) were 
randomized to pravastatin 40 mg/day (n = 2891) or placebo (n = 2913). The mean LDL-C 
reduction in this study in the active group was 32%, and the risk of developing coronary 
heart disease (CHD) was decreased by 19% over 3.2 years, which was statistically 
significant. This effect would translate into an estimated 30% risk reduction in CHD events 
over 5 years, consistent with other statin trials. Other changes in the treatment group were 
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that high density lipoprotein (HDL) C was increased by 5%, and triglycerides were 
decreased by 12% versus baseline in those placed on pravastatin. In those judged to have 
good compliance (i.e. taking medication more than 75% of the time), these alterations on the 
lipid levels were even greater at 34%, 5%, and 13%, respectively. No significant lipid 
changes were noted in the placebo group. Lipid values were virtually identical at onset of 
the study in subjects randomized to pravastatin or placebo.
Biochemical and DNA Analysis
Total cholesterol (TC), HDL-C, and triglycerides were assessed after an overnight fast, at 
baseline and at 6 months, and LDL-C was calculated by the Friedewald formula, as 
previously described.7–8 DNA was isolated from cells from this cohort and DNA samples 
from 5783 subjects were available to us. ApoE phenotype was determined on plasma 
samples by Western blotting, using the method of Havekes et al9 in the central laboratory of 
the Royal Infirmary in Scotland. Subjects were classified according to the presence of 
apoE2, apoE3, or apoE4 bands on gel blotting.
For DNA analysis we genotyped two single nucleotide polymorphisms (SNPs) in the 3’UTR 
of the LDLR gene, C44857T (rs1433099), and A44964G (rs2738466) and one SNP in the 
intron 18 T>G (rs17238540) of the HMGCR gene the using Taq Man® SNPs genotyping 
assays (Applied Biosystems, Foster City CA). The custom assays IDs are C_2018188_10, 
C_998744_10 and C__25652066_10 respectively. For reference the Genbank/EMBL 
accession numbers were NC 000019.8, mim 606945 for the LDLR gene and NC 
NC_000005.8, mim 142910. The end point was read after PCR amplification was performed 
using an Applied Biosystems 7900 HT Sequence Detection System. Genotypes with quality 
scores below the 95% were repeated and 5% blinded replicates for genotype determinations 
were performed. In addition, a total of 119 subjects or 2.2% who had the apoE4/2 phenotype 
were excluded from these analyses, as well as 246 subjects who had missing apoE 
phenotypes. These exclusions were carried out because apoE phenotype or genotype can 
affect statin induced LDL lowering response, as well as CHD risk. Subjects carrying the 
apoE4 allele have shown a lesser response in terms of LDL lowering and the highest CHD 
risk than in others, and apoE2 and apoE4 phenotypes have opposite effects in this 
regard.10–14 The subject characteristics for these individuals comprising 2621 men and 2796 
women are shown in Table 1
Statistical Analysis
Observed genotype frequencies were compared with those expected under Hardy-Weinberg 
equilibrium using a χ2 test. For data analysis, multivariable analysis of covariance 
(ANCOVA) was performed to detect associations between the lipoprotein levels at baseline 
as well as changes in response to the treatment with pravastatin at 6 month, and the LDLR 
and HMGCR genotypes adjusted for gender, body mass index, age, alcohol consumption, 
smoking status, diabetes, apoE phenotype, and country of origin, since subjects participating 
in PROSPER were either from Scotland, Ireland, or the Netherlands. Prevalence of both 
myocardial infarction (MI) and all vascular diseases (history of angina, claudication, MI, 
stroke, transient ischaemic attack, peripheral arterial disease surgery or amputation for 
vascular disease more than 6 months before study entry) at baseline, as well as incidence of 
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primary endpoints (CHD death or non-fatal MI or fatal or non-fatal stroke), and all 
cardiovascular events (primary endpoints and coronary artery bypass grafting, coronary 
angioplasty, and peripheral arterial surgery or angioplasty) was compared between carriers 
of different LDLR and HMGCR SNP genotypes using multivariable logistic regression 
analysis in all subjects and stratified by gender and treatment. All analyses were fully 
adjusted for the above covariates plus history of vascular disease, hypertension and 
randomized treatment. To evaluate the modifying effects of genotypes and gender on the 
response to treatment, gene-treatment and gene-gender interaction terms were added to the 
regression models. Lewontin’s D value was calculated to assess the linkage disequilibrium 
(LD) between the two SNPs of interest.15 Haplotype analysis including both genotyped 
markers was carried out. All analyses were performed using SAS/STAT and SAS/Genetics 
[including proc haplotype procedure] (SAS version 9.1, SAS Institute, Inc., Cary, NC). A 
two-sided p<0.05 was considered statistically significant.
Results
As can be seen from Table 1, as a group these subjects were elderly, with a mean age of 75 
years (range 70–82 years at baseline). Their mean LDL-C levels were in the moderate-risk 
category (130–160 mg/dl), as defined by the United States National Cholesterol Education 
Program. More than 50% of the men and more than 30% of the women had a history of 
vascular disease at baseline. Data on allele frequencies for the C44857T and A44964G 
polymorphisms at LDLR and i18 T>G at the HMGCR gene are shown in Table 1, along 
with the apoE phenotype distribution in this population. The distribution of genotypes from 
all the SNPs were in Hardy – Weinberg equilibrium (p>0.05, data not shown). There was no 
association with the presence of the minor allele i18 T>G at the HMGCR gene locus and 
baseline lipid, baseline vascular disease, LDL-C lowering response to pravastatin or on trial 
CHD or CVD outcomes (data not shown). For the GG genotype carriers, comprising 3.7% 
of the study population, the mean LDL-C lowering response (%) to pravastatin was -36.6% 
(n=70), while for non-carriers it was -36.0% (n=1832) in the fully adjusted model (p=ns) 
with subjects who reportedly had good compliance. Similar reductions were observed for the 
entire group of carriers (n=102) versus non-carriers (n=2657) placed on statins (ns).
Table 2 provides adjusted mean values stratified by sex. Our findings show that both men 
and women with the T allele at the C44857T locus had significantly lower levels of LDL-C 
(a difference of 2.7% or 4.0 mg/dl between TT and CC carriers in men and women 
combined, p=0.039), and this was also the case for total cholesterol (p=0.031). With regard 
to A44964G, the G allele was associated with lower TC (a difference of 1.2% or 2.5 mg/dl 
between GG and AA carriers, p=0.002,), lower LDL-C (3.3% or 4.5 mg/dl, p=0.001), and 
higher TG which reached statistical significance in men only (Table 2). GG carriers also had 
significantly higher TG levels in a combined group of men and women (with a difference of 
6.1% or 9.3 mg/dl compared to AA carriers, p=0.009, data not shown).
Haplotype analysis detected that the two SNPs in the 3’UTR LDLR region under study were 
in linkage disequilibrium (D’=0.997) and revealed three common haplotypes: C44857T[C]- 
A44964G[A], C44857T[C]- A44964G[G] and C44857T[T]- A44964G[A] present in 49%, 
25% and 26%, respectively, and a very rare haplotype C44857T[T]- A44964G[G] present in 
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less than 0.1% of the participants. Carriers for the C44857T[T]- A44964G[A] had 2.2% 
lower TC levels and 3% lower LDL-C levels per each haplotype copy than those with the 
C44857T[C]- A44964G[A] haplotype (p=0.001), while individuals with the C44857T[C]- 
A44964G[G] haplotype had 1.74% lower TC levels (p=0.013) and 3.1% lower LDL-C 
levels (p=0.0007) than those with the C44857T[C]- A44964G[A] haplotype.
In Table 3, data on response to pravastatin in terms of percent LDL-C lowering are 
provided. Carriers for the minor allele at the C44857T SNP had a significantly, but modestly 
better LDL-C lowering response than non carriers (p=0.03). It should be noted that our 
analysis was based on people who reportedly had good compliance (i.e. taking their 
medication more than 75% of the time). However, the same effects were observed in the 
entire group (data not shown).
In Table 4, the hazard ratios (HR) on trial for new onset of the primary endpoint and all 
cardiovascular events are shown for the LDLR SNPs. Those with the TT genotype at 
C44857T had a HR of 0.66 (CI 0.48–0.92) for the primary endpoint in the fully adjusted 
model when compared to non-carriers. This association was mostly driven by males in the 
pravastatin group (Table 4). No such associations were noted in individuals on placebo or in 
women (data not shown). Regarding the A44964G for the primary endpoint and 
cardiovascular events, carriers of the GG genotype had a higher HR than non-carriers with 
the greatest risk in men on pravastatin. For primary endpoints, the adjusted HR was 1.32 (CI 
1.02–1.71) in all individuals in the fully adjusted model and 2.23 (CI 1.37–3.63) in males on 
pravastatin. For cardiovascular events, the adjusted HR is 1.29 (CI 1.00–1.65) in the fully 
adjusted model and HR 1.97 (CI 1.23–3.16) in males on pravastatin. There was no 
significant difference in HR in all subjects on placebo or in women on pravastatin (Table 4). 
In haplotype analysis, those carrying the C44857T[T]- A44964G[A] haplotype had a lower 
risk for primary endpoints (HR 0.69, CI 0.52–0.90) and cardiovascular events (HR 0.74, CI 
0.57–0.95) than the C44857T[C]- A44964G[G] haplotype carriers. The same was observed 
in subjects on pravastatin (HR 0.37, CI 0.21–0.66). In addition, in the men on pravastatin, 
carriers of C44857T[C]- A44964G[A] showed a trend toward lower risk of primary 
endpoints as compared to the C44857T[C]- A44964G[G] carriers (HR 0.59, CI 0.36–0.99) 
and lower risk of cardiovascular events (HR 0.62, CI, 0.38–1.00) (data not shown). The odds 
ratios (OR) of developing any form of vascular disease (angina, claudication, MI, stroke, 
transient ischemic attack, coronary angioplasty or bypass, or peripheral vascular surgery or 
angioplasty) or MI at baseline was not significantly associated with any of the SNPs (data 
not shown).
Discussion
Genetic variation at the HMGCR locus has been reported to affect LDL-C lowering 
response to pravastatin6. Chasman et al examined 148 SNPs at 10 candidate gene loci 
following 6 months of pravastatin therapy (ABCG5, ABCG8, APOB, APOE, CETP, 
CYP3A4), CYP3A5, FDFT1, HMGCR, and LDLR) in 1536 subjects and reported that the 
rare G allele at one of two tightly linked SNPs, (frequency 0.033) at the intron 18 SNP i18 
T>G was related to a significantly less percent LDL-C lowering response (−27.2% for 
heterozygotes, n=100, versus −34.3% for non-carriers, n= 1,418). In our study we noted a 
Polisecki et al. Page 5













lower frequency for the rare allele at this SNP (0.019) than that reported by Chasman et al, 
possibly because their population was more diverse. We also saw no differences with regard 
to the presence or absence of this rare allele at HMGCR and baseline lipids, baseline 
vascular disease, percent LDL-C lowering response to pravastatin, or on trial CHD or CVD 
events. Similar to our data, a recent study by Singer et al also found no associations between 
this SNP and response to fluvastatin in the ALERT study16. Chasman et al also examined 
SNPs at the LDLR locus including one (A44964G) that we have examined. The authors 
reported no significant differences with regard to A44964G and percentage LDL-C lowering 
response to pravastatin, consistent with our findings6.
Our collaborators H. Muallem and N. Maeda examined LDLR SNPs in the Atherosclerosis 
Risk in Communities (ARIC) study. They also noted that the T allele at C44857T was 
associated with significantly lower LDL-C levels, and these differences were statistically 
significant for the men, but not for women. In our studies we also noted lower LDL-C levels 
associated with this allele, and these differences were statistically significant in women, as 
well as in the entire group after adjustment. With regard the G allele at A44964G at the 
LDLR locus Muallem et al noted no significant effects on baseline lipids in ARIC, but they 
did not evaluate effects on TG levels. In our studies we found that this allele was associated 
with significant increases in triglyceride levels in the entire group as well as in men only, 
and significant decreases in LDL-C values in men only. In terms of haplotype analysis, 
Muallem et al reported that those with the C44857T[T]- A44964G[A] haplotype had lower 
LDL-C and TC levels, while those with the C44857T[C]- A44964G[A] haplotypes had 
higher LDL-C and TC. In our view these findings are driven by the C44857T allele, since 
this is the one that changes in these two haplotypes. We also found that those with 
C44857T[T]- A44964G[A] haplotype had lower levels of LDL-C (3.0%, p=0.0014) than 
subjects with the major haplotype C44857T[C]- A44964G[A], and that those with the 
C44857T[C]- A44964G[G] haplotype had 3.1% lower levels of LDLC (p=0.0007). In 
summary, carriers of haplotypes which include one of the alleles that are associated with 
lower LDL-C for any of the two SNPs, have a lower LDL-C levels than the major 
C44857T[C]- A44964G[A] haplotype.
Another novel feature of our study is that we have examined effects of these SNPs on 
cardiovascular endpoints. We report that the minor allele for the C44857T was associated 
with lower risk for CHD on trial, which is probably related to lower LDLC levels17–19. 
Regarding the A44964G SNP, the minor allele is associated with higher risk of CHD on trial 
and in the haplotype analyses the HR is, in our view, driven by the A allele. These data 
suggest that carriers for the minor allele not only have higher TG levels, but also have higher 
CHD risk, especially in males on pravastatin. In conclusion, our overall data are consistent 
with the concepts that variation at the HMGCR_i15T>G SNP is not associated with baseline 
lipids, statin response, or CVD risk, but that variation at LDLR SNPs C44857T and 
A44964G can affect baseline lipids, statin response and CVD risk.
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Age, years 74.99 (3.26) 75.64 (3.38) b
BMI, kg/m2 26.56 (3.59) 27.12 (4.66) b
History Diabetes mellitus, N (%) 324 (12.36) 251 (8.98) b
History Hypertension, N (%) 1333 (50.86) 2026 (72.46) b
History Vascular Disease, N (%) 1371 (52.31) 1033 (36.95) b
Current smoking, N (%) 847 (32.32) 586 (20.96) b
Alcohol consumption, N (%) 1851 (70.62) 1165 (41.67) b
Total Cholesterol, mg/dl 207.0 (30.7) 231.9 (34.5) b
LDL-Cholesterol, mg/dl 138.5 (27.8) 154.9 (35.3) b
HDL-Cholesterol, mg/dl 45.6 (12.2) 53.0 (13.4) b
VLDL-Cholesterol, mg/dl 23.0 (13.6) 24.0 (13.7)
Triglyceride, mg/dl 132.4 (64.3) 140.6 (59.4) b
apoA-I, mg/dl 124.4 (22.2) 139.9 (24.1) b
apoB, mg/dl 110.6 (21.3) 119.1 (22.6) b
apoE 2/2 + 2/3, % 342 (13.05) 315 (11.27)
apoE 3/3, % 1655 (63.14) 1837 (65.70)
apoE 3/4 + 4/4, % 624 (23.81) 644 (23.03)
LDLR_C44857T- rs1433099 MAF T:0.26
LDLR_A44964G- rs2738466 MAF G:0.25
HMGCR_i18 T>G- rs17238540 MAF G:0.019
a
means (SD) unless otherwise specified; differences between men and women were assessed using a t-test for continuous variables, and χ2 test for 
binary traits; MAF – minor allele frequency.
b
p<0.001, mean values are presented, apoE 2/4 carriers were excluded from the analysis (see Material and Methods section).
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